The fact that it reliably produces an increase in the 4R tau isoforms would also allow it to be used to screen, test and develop candidate drugs targeting tau alternative splicing – something that would not be possible with overexpression-based models of tauopathy. The gene discussed is MAPT; the disease is tauopathy.